Jazz Pharmaceuticals plc and AbCellera Biologics Inc. announced a pre-clinical research collaboration to develop next-generation antibodies for cancer treatment on June 17, 2026 [1, 3].
This partnership aims to expand Jazz Pharmaceuticals' oncology pipeline by targeting solid tumors, including gastrointestinal cancers. By leveraging AbCellera's discovery platform, the companies intend to accelerate the creation of multispecific antibodies that engage T-cells to attack malignant cells more effectively [2, 4].
The agreement includes a research collaboration, an option, and a licensing arrangement [1, 2]. The total value of the deal could reach $876 million, reporting said [3].
The collaboration focuses on T-cell-engaging multispecific antibodies, which are designed to bridge the immune system's T-cells to specific targets on tumor cells [2, 5]. This approach is intended to improve the precision and efficacy of treatments for solid tumors, which have historically been more difficult to treat than blood-based cancers [4].
Jazz Pharmaceuticals is utilizing this agreement to increase its research capabilities in the oncology space. The pre-clinical nature of the work means the antibodies are currently in the discovery and testing phase and have not yet entered human clinical trials [1, 2].
“The total value of the deal could reach $876 million.”
This agreement signals a strategic shift for Jazz Pharmaceuticals to deepen its footprint in oncology through high-value biotechnology partnerships. By targeting solid tumors, a challenging area of cancer research, the company is betting on multispecific antibody technology to create a new generation of therapies that can more effectively trigger an immune response within the tumor microenvironment.
